Efficacy of High-Intensity Atorvastatin for Asian Patients Undergoing Percutaneous Coronary Intervention.
Statins have proven cardioprotective effects, but higher doses are accompanied by various concerns and may not lead to superior clinical outcomes in Chinese/Asian populations.



We designed a trial to test the efficacy of high-intensity statin therapy for the reduction of periprocedural myocardial infarction (MI) and 1-year major adverse cardiovascular events (MACEs, including cardiovascular death, spontaneous MI, unplanned revascularization) in an Asian population.



A total of 798 Chinese patients with stable angina or acute coronary syndrome (ACS) were randomized to high-intensity atorvastatin (80 mg/d before percutaneous coronary intervention [PCI] and 40 mg/d thereafter for 1 year, n = 400) or moderate-intensity atorvastatin (20 mg/d for 1 year, n = 398). The primary end point was 1-year incidence of MACEs.



In patients with stable angina, 1-year MACE rates were not significantly different between moderate- and high-intensity groups (7.6% vs 5.7%, P = 0.53). In contrast, in patients with ACS, the 1-year MACE rate was significantly higher in the moderate- than in the high-intensity atorvastatin group (16.8% vs 10.1%, P = 0.021; adjusted hazard ratio = 1.71, 95% CI = 1.08 to 2.77, P = 0.021).



Whereas stable angina patients derive similar benefit from moderate- and high-intensity atorvastatin therapy over the duration of 1 year after PCI, high-intensity statin therapy is superior in ACS patients.
Xuanwu Hospital Capital Medical University, Beijing, China.
Zhi
Z
Liu
Mayo Clinic, Rochester, MN, USA.
Herrmann
H
Joerg
Xuanwu Hospital Capital Medical University, Beijing, China.
Hengjian
H
Hao
Xuanwu Hospital Capital Medical University, Beijing, China.
Ji
J
Xu
Xuanwu Hospital Capital Medical University, Beijing, China.
Shaodong
S
Hu
Xuanwu Hospital Capital Medical University, Beijing, China.
Boyu
B
Li
Xuanwu Hospital Capital Medical University, Beijing, China.
Cheng
C
Sang
Xuanwu Hospital Capital Medical University, Beijing, China.
Jinggang
J
Xia
Xuanwu Hospital Capital Medical University, Beijing, China.
Yanyan
Y
Chu
Xuanwu Hospital Capital Medical University, Beijing, China xwyy168@sina.com.
Dong
D
Xu
D054058:Acute Coronary Syndrome / Q000097:blood / Q000601:surgery; D000368:Aged; D060050:Angina, Stable / Q000097:blood / Q000601:surgery; D000069059:Atorvastatin / Q000008:administration & dosage* / Q000627:therapeutic use*; D002681:China; D003627:Data Interpretation, Statistical; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use*; D015994:Incidence; D008055:Lipids / Q000097:blood; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control*; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000379:methods*; D016896:Treatment Outcome; D019210:Troponin I / Q000097:blood
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D019210:Troponin I; D000069059:Atorvastatin
atorvastatin; coronary artery disease; percutaneous coronary intervention; prognosis